ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Influence of HER2 overexpression and prognosis in esophagogastric cancer

Influence of HER2 overexpression and prognosis in esophagogastric cancer
Study Disease stage Tumor site n Treatment HER2-positive rate (%) Association with survival: Median OS in HER2-positive versus HER2-negative patients
AVAGAST[1] Metastatic* Gastric, GEJ 712 FP with and without bevacizumab NR Null: 9.8 versus 10.5 months (NSS)
Europe/USA collaborationΔ[2] Metastatic Gastric, GEJ 381 Chemotherapy 20 Favorable: 13.9 versus 11.4 months (p = 0.047)
EXPAND[3,4] Metastatic* Gastric, GEJ 679 FP with and without cetuximab 21

Favorable in control arm: 14.0 versus 9.7 months (NSS)

Favorable in treatment arm: 13.3 versus 9.2 months (NSS)
REAL3[5] Metastatic* Gastric, GEJ, esophagus 174 EOC with and without panitumumab 16 Null: Details not reported
ACTS-GC[6] Operable Gastric 829 Surgery with and without S-1 13.6 Null: 5-year OS 64 versus 68% (NSS)
MAGIC[7] Operable Gastric, GEJ, esophagus 415 Surgery with and without ECF 10.9 Null: Details not reported
INT0116[8] Operable Gastric, GEJ 258 Surgery with and without chemoradiotherapy 10.9

Null in control arm: 22 versus 24 months (p = 0.76)

Adverse in chemoradiotherapy arm: 16 versus 44 months (p = 0.025)
HER2: human epidermal growth factor receptor 2; OS: overall survival; GEJ: gastroesophageal junction; FP: fluoropyrimidine plus cisplatin; NR: not reported; NSS: not statistically significant; USA: United States of America; EOC: epirubicin, oxaliplatin, and capecitabine; S-1: ftorafur (tegafur), gimeracil, and oteracil; ECF: epirubicin, cisplatin, and fluorouracil.
* Includes locally advanced unresectable.
¶ Analysis combined all patients.
Δ Pooled analysis of six first-line trials utilizing various combinations of fluorouracil, oxaliplatin, cisplatin, and/or docetaxel.
References:
  1. Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012; 30:2119.
  2. Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012; 23:2656.
  3. Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancel Oncol 2013; 14:490.
  4. Lordick F, Kang YK, Salman P, et al. Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study. J Clin Oncol 2013; 31:abstr 4021.
  5. Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14:481.
  6. Terashima M, Kitada K, Ochiai A, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 2012; 18:5992.
  7. Okines AF, Thompson LC, Cunningham D, et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol 2013; 24:1253.
  8. Gordon MA, Gundacker HM, Benedetti J, et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 2013 [ahead of print].
Graphic 89512 Version 4.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟